MET and glioma: Inhibition of MET with capmatinib was studied in a phase II trial in adult GBM and showed no clear activity while the MET inhibitor bozitinib was tested in 18 pediatric patients with recurrent high-grade glioma with partial response seen in only 2 patients (77).